Patient and family engagement is important for ensuring positive clinical outcomes in schizophrenia, which can affect a patient's insight and judgement, explained John Kane, MD, professor and chairman, department of psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Zucker Hillside Hospital.
Patient and family engagement is important for ensuring positive clinical outcomes in schizophrenia, which can affect a patient's insight and judgement, explained John Kane, MD, professor and chairman, department of psychiatry, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Zucker Hillside Hospital.
TranscriptHow important is patient and family engagement for ensuring medication adherence and other positive clinical outcomes in schizophrenia?
So, patient engagement is key. We really are not going to succeed in helping people with their illness unless they are engaged in treatment, and that’s a big challenge because an illness like schizophrenia can affect insight and judgment. People sometimes don’t appreciate the fact that they are ill, that they’re experiencing an illness. We also know that treatment may require a long time. People might need to stay in treatment to prevent a relapse from occurring.
So, engagement and sustained engagement is really key. And when the illness first begins, that can be one of the biggest challenges—sustained engagement. Particularly if somebody, ironically, is doing well, they feel they no longer need treatment, and in fact those individuals have a lot to lost if they do get sick again. So, that’s a little bit of a paradox, in a way, for some people. It’s hard for them to appreciate the need for prophylactic treatment, even when they’re feeling well.
In terms of the family, that’s extremely important, as well. Particularly in the early phases of the illness, the young person is often still living with the family or very involved with the family. They need to be educated as to the nature of the illness, what’s going on. So, they’re engagement is also very, very important.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More